Chronic Allograft Nephropathy Score Before Sirolimus Rescue Predicts Allograft Function in Renal Transplant Patients

Transplantation Proceedings

Volumn 39, Issue 1, 2007, Pages 94-98

  Basu, A ^a   Falcone, J L ^a   Tan, H P ^a   Hassan, D ^a   Dvorchik, I ^a   Bahri, K ^a   Thai, N ^a   Randhawa, P S ^a   Marcos, A ^a   Starzl, T E ^a   Shapiro, R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846561554     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.10.017     Document Type: Article

References (22)

1. Cecka J.M. The UNOS Scientific Renal Transplant Registry-2000. In: Cecka J.M., and Teraski P.I. (Eds). Clinical Transplants 2000. 1st Ed. (2001), UCLA Immunogenetics Center, Los Angeles, Calif 1
2. Solez K., Axelsen R.A., Benediktsson H., et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 44 (1993) 411
3. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 712
4. Nankivell B.J., Borrows R.J., Fung C.L.-S., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
5. Flechner S.M. Calcineurin inhibitor free protocols in organ transplantation. Curr Opin Organ Transpl 9 (2004) 383
6. Solez K., Vincenti F., and Filo R.S. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing Tacrolimus with Cyclosporine: a report of the FK 506 kidney transplant study group. Transplantation 66 (1998) 1736
7. McKane W., Kangana C., Preston R., et al. Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil. Transplant Proc 33 (2001) 1224
8. Chueh S.-C.J., and Kahan B.D. Clinical application of sirolimus in renal transplantation: an update. Transplant Int 18 (2005) 261
9. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31 (1998) 335
10. Basu A., Tan H.P., and Shapiro R. Sirolimus. Curr Opin Organ Transpl 8 (2003) 299
11. Morales J.M., Wrammer L., Kreis H., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2 (2002) 436
12. Weber T., Abendroth D., and Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transplant Int 18 (2005) 151
13. Basu A., Ramkumar M., Gray E., et al. Sirolimus as 'rescue' treatment in kidney and kidney-pancreas transplantation in patients receiving tacrolimus-based immunosuppression (abstract). Am J Transplant 3 (2003) 353
14. Egidi M.F., Cowan P.A., Naseer A., et al. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 35 (2003) 131S
15. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
16. Starzl T.E., Murase N., Abu-Elmagd K., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 361 (2003) 1502
17. Shapiro R., Jordan M., Basu A., et al. Kidney transplantation under a tolerogenic regimen of recipient pre-treatment and low-dose postoperative immunosuppression, with subsequent weaning. Ann Surg 238 (2003) 520
18. Shapiro R., Basu A., Tan H., et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 200 (2005) 505
19. Sankaranarayanan N., Balarezo F., Alleman K., et al. Chronic allograft damage index (CADI) scoring at conversion from calcineurin inhibitors (CI) to sirolimus predicts renal outcome in kidney transplant recipients (abstract). Am J Transplant 4 (2004) 296
20. Isoniemi H., Taskinen E., and Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 58 (1994) 1195
21. Watson C.J.E., Firth J., Williams P.F., et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5 (2005) 2496
22. Mota A., Arias M., Taskinen E.I., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953